Lumibird SA (LBIRD.PA) Stock
Lumibird SA

Company profile
Lumibird SA reported revenue of 210.06 million EUR for fiscal year 2024, up 1.7% from fiscal year 2023, and net income of 5.70 million EUR. That is a net profit margin of 2.7% for fiscal year 2024. Its largest business segment, Photonic, brought in 50% of segment revenue in fiscal year 2025; Other Countries was the largest region with 49%. Our analysis of its filings shows revenue growing from 194.29 million EUR in fiscal year 2022 to 210.06 million EUR in fiscal year 2024, 4.0% a year on average. Lumibird SA reports about 1,078 full-time employees.
What stands out
- Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Lumibird SA
Lumibird SA designs, manufactures, and sells various lasers for scientific, industrial, and medical applications in France, Hong Kong, the United States, Germany, South Korea, China, and Austria. The company operates through Photonics and Medical divisions. It offers fiber lasers and amplifiers, high power fiber lasers, and solid-state lasers, laser diodes and components; and doppler wind LiDAR, time-of-flight LiDAR and rangefinders, military laser rangefinders, and medical and ophthalmological solutions. The company serves defense and space, environment, topography and safety, industry and science, and science and healthcare industries. Lumibird SA was incorporated in 1970 and is headquartered in Lannion, France. Lumibird SA is a subsidiary of ESIRA.
Largest shareholders
- Marc Paul Marcel Le Flohic51.46 %51.46%
- Ruth Wertheimer6.192 %6.19%
- Amiral Gestion SA3.21%
- Lumibird2.04%
- Renta 4 Gestora SGIIC SA0.84%
Share of the company, as of May 18, 2026
Leadership
- Marc Le Flohic — CEO & Chairman, 62
- Jean-Marc Gendre — Deputy General Director & CEO of Lumibird Medical
- Andrew Moysey — Group Chief Financial Officer
- Frederic Chiquet — Chief Corporate Social Responsibility Officer
- Sonia Rutnam — Chief Transformation Officer
In the news
- Europe Photodynamic Therapy Market Size, Trends, Leading Applications and Pricing Benchmarks (2025-2033) Featuring Gladerma, Sun Pharmaceutical, Biofrontera, Lumibird, Bausch Health Companies and More
- 3 European Stocks Estimated To Be Up To 36.2% Below Intrinsic Value
- European Value Stocks: STIF Société anonyme Among 3 Companies Estimated Below Intrinsic Value
- LUMIBIRD PHOTONICS SWEDEN SECURES MAJOR NAVAL CONTRACT FOR VIDAR RANGEFINDERS WITH SAAB AND DALO
How much revenue does Lumibird SA make?
Lumibird SA reported 210.06 million EUR in revenue for fiscal year 2024, up 1.7% from 206.55 million EUR in fiscal year 2023.
What is Lumibird SA's largest business segment?
Photonic, with 113.41 million EUR or 50% of segment revenue in fiscal year 2025. Next: Medical (50%).
Where does Lumibird SA make most of its revenue?
Other Countries: 49% of revenue by region in fiscal year 2025, followed by United States (20%).
What companies are similar to Lumibird SA?
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Theraclion SA (ALTHE.PA), Mauna Kea Technologies SA (ALMKT.PA).
How has Lumibird SA's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 129.51 million EUR; FY2021, 166.39 million EUR; FY2022, 194.29 million EUR; FY2023, 206.55 million EUR; FY2024, 210.06 million EUR.
Company Information
Data as of .
How to cite: DataPorium, “Lumibird SA (LBIRD.PA)”, data as of May 18, 2026, https://dataporium.tech/stocks/LBIRD.PA